The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:307-308 January 18, 2007 Number 3
NextNext

AMG 531 for Chronic ITP

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Bussel, J. B.
-PubMed Citation
To the Editor: Bussel et al. (Oct. 19 issue)1 justify the rationale for using the thrombopoiesis-stimulating drug AMG 531 in chronic immune thrombocytopenic purpura (ITP) by citing previous reports on abnormalities of megakaryocytic survival and maturation in this disorder. However, studies of defective platelet production in ITP have yielded conflicting results,2,3 and the present study provides no evidence of such an abnormality in any patient. Furthermore, there is no information on changes in megakaryocytic mass or serum thrombopoietin levels after treatment with AMG 531, and it is unclear whether this drug truly abrogates abnormalities of platelet production. In addition, the . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.